40959_2021_112_MOESM1_ESM.tif (593.16 kB)
Additional file 1 of Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review
figure
posted on 2021-07-07, 03:28 authored by Shingo Kazama, Ryota Morimoto, Yuki Kimura, Naoki Shibata, Reina Ozaki, Takashi Araki, Takashi Mizutani, Hideo Oishi, Yoshihito Arao, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Kenji Furusawa, Tomoya Shimokata, Takahiro Okumura, Yasuko K. Bando, Yuichi Ando, Toyoaki MuroharaAdditional file 1: Supplemental Figure S1. Landmark analysis, excluding patients who died within 3 months. Kaplan–Meier survival analysis for all-cause mortality. The prognosis of patients with immune-related adverse events (irAEs) was significantly better than that of patients without irAEs (P < 0.001). This was also detected in patients with a cardiovascular history (P = 0.014) and in those without a cardiovascular history (P = 0.001).
